Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Age 8 weeks (56-63 days) at the time of first vaccination~* Infants in good general health, eligible to be vaccinated according to the Polish national vaccination program. The same health criteria apply as used in well-baby clinics when a child receives a vaccination, e.g. also children with a small increase in temperature (\< 38.5° C) or with a common cold (runny nose etc) are seen as children with normal health.~* The parent(s)/legally representative(s) have to be willing and able to allow their child to participate in the trial according to the described procedures~* Presence of a signed informed consent in which the parent(s)/legally representative(s) have given written informed consent after receiving oral and written information (signature from one parent in case of single-parent family).~Exclusion Criteria:~* Any IPV or OPV dose~* Known or suspected allergy against any of the vaccine components~* History of unusual or severe reactions to any previous vaccination administration of plasma (including immunoglobulins) or blood products prior and during the study~* Any vaccination less than 14 days before or after each vaccination with the IMP~* History of any neurological disorder including epilepsy or febrile seizures~* Any infectious disease at the time of screening and/or inclusion that might interfere with the results of the study~* Present evidence of serious disease(s) demanding immunosuppressive medical treatment, like cytostatics and prednisolones, that might interfere with the results of the study~* Any known or suspected primary or secondary immunodeficiency~* Communication problems interfering in the study realization according to the judgment of the investigator~* Bleeding disorders and use of anticoagulants~* Premature birth (\<37 weeks)~* Participation in another clinical trial

- Gender: ALL
- Minimum Age: 56 Days
- Maximum Age: 63 Days
- Healthy Volunteers: t

Study Arms:
- Low dose Sabin-IPV (Type: EXPERIMENTAL): Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses.
- Low dose adjuvanted Sabin-IPV (Type: EXPERIMENTAL): Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 2.5, 4, 8 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses.
- Middle dose Sabin-IPV (Type: EXPERIMENTAL): Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses.
- Middle dose adjuvanted Sabin-IPV (Type: EXPERIMENTAL): Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses.
- High dose Sabin-IPV (Type: EXPERIMENTAL): Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses.
- High dose adjuvanted Sabin-IPV (Type: EXPERIMENTAL): Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses.
- Conventional IPV (Type: ACTIVE_COMPARATOR): Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose.~Infants receive three injections with an interval of 8 weeks between doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete